EVALUATION STUDIES
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

An innovative absorbable coating for the polybutester suture.

The polybutester (PBE) suture has been coated with an absorbable polytribolate polymer that is composed of glycolide (9%), epsilon-caprolactone (51%), and poloxamer 188 (40%) to reduce its drag forces. It is the purpose of this study to document the influence of this coating on the biomechanical performance of both PBE sutures and polypropylene (PP) sutures. The performance parameters evaluated were breaking strength, elongation, stiffness, knot security, knot run down, and tissue drag. The breaking strength of PP sutures was remarkably similar to that of coated and uncoated PBE sutures. In size 5/0 PP sutures, the sutures exhibited considerably greater elongation at knot break than did comparably sized PBE sutures. The PBE suture elongated under low loads, but returned to its original length when the load was removed. In contrast, the PP suture elongated irreversibly at high loads, exhibiting creep. Coated and uncoated PBE sutures exhibited less stiffness than PP sutures and exhibited limited memory after removal from the suture package. Coating the PBE suture markedly reduced its drag forces in musculoaponeurotic, colonic, and vascular tissue. Knot security with the coated PBE suture was achieved with only one more throw than with comparably sized uncoated PBE sutures. On the basis of the results of this study, coating the PBE suture represents another major advance in suture performance.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Urinary Tract Infections: Core Curriculum 2024.American Journal of Kidney Diseases 2023 October 31

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app